RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca plc
  • Cancer Research UK

This publication has 24 references indexed in Scilit: